GMAB vs SNY: fair value comparison
Genmab A/S and Sanofi · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, SNY currently sits closer to the top of our discount ranking. GMAB carries the stronger quality grade.
| GMAB | SNY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $28.68 | $42.95 |
| 12-month range | $25.45–$33.27 | $41.63–$47.40 |
| Sector rank | #45 of 113 Healthcare | #41 of 113 Healthcare |
| Quality grade | A | B |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: GMAB fair value analysis · SNY fair value analysis